Thermo Fisher Scientific Acquires Brammer Bio for $1.7 Billion

Thermo Fisher Scientific Acquires Affymetrix

March 31, 2016

Biotechnology

Thermo Fisher Scientific has completed its acquisition of Affymetrix for $14.00 per share in cash, representing an approximate total purchase price of $1.3 billion, following approval by Affymetrix stockholders. The deal brings Affymetrix's genetic analysis products and expanded antibody portfolio into Thermo Fisher's life sciences offerings to strengthen its capabilities in biosciences and clinical/applied markets.

Agilent Technologies Acquires BIOVECTRA for $925M

July 22, 2024

Pharmaceuticals

Agilent Technologies has acquired BIOVECTRA, a Canada-based contract development and manufacturing organization (CDMO), for $925 million. The acquisition — a purchase from H.I.G. Capital — expands Agilent's CDMO capabilities across biologics, HPAPIs, pDNA/mRNA and LNP formulation, and integrates BIOVECTRA into Agilent's Diagnostics and Genomics Group.

Thermo Fisher Scientific Acquires PPD, Inc.

December 8, 2021

Healthcare Services

Thermo Fisher Scientific completed the acquisition of PPD, Inc. for $17.4 billion in cash, plus the assumption of approximately $3.0–$3.5 billion of net debt. The deal brings PPD's global clinical research and laboratory services into Thermo Fisher's Laboratory Products and Services segment, expanding Thermo Fisher's capabilities in clinical development and expected to generate approximately $125 million of synergies by year three.

Charles River Laboratories Acquires Vigene Biosciences

May 17, 2021

Biotechnology

Charles River Laboratories agreed to acquire Vigene Biosciences, a Rockville, Maryland-based gene therapy CDMO, for $292.5 million in cash plus up to $57.5 million in contingent payments. The acquisition expands Charles River's cell and gene therapy contract development and manufacturing capabilities—adding CGMP viral vector and plasmid DNA production—and is expected to close in early Q3 2021.

Bruker Corporation Acquires PhenomeX Inc.

August 17, 2023

Biotechnology

Bruker Corporation agreed to acquire PhenomeX Inc. in an all-cash transaction valued at roughly $108 million (purchase price $1.00 per share). PhenomeX — formed from the combination of Berkeley Lights and IsoPlexis and provider of single-cell biology instruments, software and reagents — will be folded into a Bruker subsidiary, marking Bruker’s entry into single-cell biology research tools and complementing its spatial biology offerings.

Bruker Corporation Acquires Canopy Biosciences, LLC

September 11, 2020

Biotechnology

Bruker Corporation has acquired Canopy Biosciences, LLC to strengthen its targeted multi-omics and high-plex biomarker imaging capabilities, adding Canopy's ChipCytometry platform and multi-omics services. Financial terms were not disclosed; Ampersand Capital Partners was identified as Canopy's lead investor.